References

1. Chang, B. S.; Lowenstein, D. H. N. Engl. J. Med. 2003, 349, 1257-1266.

2. McAuley, J. W; Biederman, T S.; Smith, J. C.; Moore, J. L. Ann. Pharmacother. 2002, 36, 119-129.

4. Rogawski, M. A.; Loscher, W Nat. Rev. Neurosci. 2004, 5, 553-564.

5. Annegers, J. F Am. J. Managed Care 1998, 4, S453-S462.

6. Helmers, S. L.; Griesemer, D. A.; Dean, J. C.; Sanchez, J. D.; Labar, D.; Murphy, J. V; Betti, D.; Park, Y D.; Shuman, R. M.; Morris, G. L., III.

Neurologist 2003, 9, 160-164.

7. Fisher, R. S. In Pharmacological Management of Neurological and Psychiatric Disorders; Enna, S. J., Coyle, J. T, Eds.; McGraw-Hill: New York, 1998, pp 459-503.

8. Benbadis, S. R.; Tatum, W O., IV Am. Fam. Physician 2001, 64, 91-98.

10. LaRoche, S. M.; Helmers, S. L. JAMA 2004, 291, 605-614.

12. Rogawski, M. A.; Loscher, W Nat. Med. 2004, 10, 685-692.

13. Wirrell, E.; Farrell, K.; Whiting, S. Can. J. Neurol. Sci. 2005, 32, 409-418.

14. Commission on Classification and Terminology of the International League against Epilepsy. Epilepsia 1989, 30, 389-399.

15. Sirven, J. I.; Waterhouse, E. Am. Fam. Physician 2003, 68, 469-476.

17. Yuan, P X.; Huang, L. D.; Jiang, Y M.; Gutkind, J. S.; Manji, H. K.; Chen, G. J. Biol. Chem. 2001, 276, 31674-31683.

18. Turnbill, J.; Lohi, H.; Kearney, J. A.; Rouleau, G. A.; Delgado-Esutea, A. V; Meisler, M. H.; Cossette, P; Minassian, B. A. Hum. Mol. Genet. 2005, 14, 2491-2500.

19. Mulley, J. C.; Scheffer, I. E.; Harkin, L. A.; Berkovic, S. F; Dibbens, L. M. Hum. Mol. Genet. 2005, 14, R243-R249.

21. Andermann, F; Kobyashi, E.; Andermann, E. Epilepsia 2005, 46, 61-67.

23. Hoffman, W H.; Haberly, L. B. J. Neurophysiol. 1996, 76, 1430-1438.

24. Holopainen, I. E. Neurochem. Res. 2005, 30, 1521-1528.

25. Timpe, L. C.; Jan, L. Y J. Neurosci. 1987, 7, 1307-1317.

26. Sarkisian, M. R. Epilepsy Behav. 2001, 2, 201-216.

27. White, H. S.; Woodhead, J. H.; Wilcox, K. S.; Stables, J. P.; Kupferberg, H. S.; Wolf, H. H. In Antiepileptic Drugs, 5th ed.; Levy, R. H., Mattson, R. H., Meldrum, B. S., Perruca, E., Eds.; Lippincott Williams and Wilkins: Philadelphia, PA, 2002, pp 36-48.

28. Heinrichs, S. C.; Seyfried, T. N. Epilepsy Behav. 2005, 8, 5-38.

30. Porter, R. J. In Antiepileptic Drugs, 5th ed.; Levy, R. H., Mattson, R. H., Meldrum, B. S., Perruca, E., Eds.; Lippincott Williams and Wilkins: Philadelphia, PA, 2002, pp 58-65.

32. Czuczwar, S. J.; Borowicz, K. K. Epilepsy Res. 2002, 52, 15-23.

33. Meijer, J. W A.; Meinardi, H.; Binnie, C. D. In Discoveries in Pharmacology: Vol. 1, Pyscho- andNeuro-pharmacology; Parnham, M. J., Bruinvels, J., Eds.; 1983; Elsevier: Amsterdam, the Netherlands, pp 447-488.

34. Sneader, W Drug Discovery. The Evolution of Modern Medicines; Wiley: Chichester, UK, 1985, pp 41-47.

35. McNamara, J. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th ed.; Brunton, L. L., Lazo, J. S., Parker, K. L., Eds.; McGraw-Hill: New York, 2006, pp 501-525.

36. Giardina, W J.; Dart, M. J.; Harris, R. R.; Bitner, R. S.; Radek, R. J.; Fox, G. B.; Chemburkar, S. R.; Marsh, K. C.; Waring, J. F; Hui, J. Y et al. Epilepsia 2005, 46, 1349-1361.

37. Ambrosio, A. F; Soares-Da-Silva, P.; Carvalho, C. M.; Caivalho, A. P. Neurochem. Res. 2002, 27, 121-130.

38. Knutsen, L. J. S.; Andersen, K. E.; Lau, J.; Lundt, B. F; Henry, R. F; Morton, H. E.; N®rum, L.; Petersen, H.; Stephensen, H.; Suzdak, P D. et al. J. Med. Chem. 1999, 42, 3447-3462.

39. Betrand, S.; Ng, G. Y K.; Puriasi, M. G.; Wolfe, S. E.; Severidt, M. W; Nouel, D.; Robitaille, R.; Low, M. J.; O'Neill, G. P.; Metters, K. et al. J. Pharmacol. Exp. Ther. 2001, 298, 15-24.

40. Sills, G. J. Curr. Opin. Pharmacol. 2006, 6, 108-113.

42. Stepien, K.; Tomaszewski, M.; Czuczwar, S. J. Pharmacol. Rep. 2005, 57, 719-733.

44. Williams, M.; Coyle, J. T; Shaikh, S.; Decker, M. W Annu. Rep. Med. Chem. 2001, 36, 1-10.

45. McGaraughty, S.; Cowart, M.; Jarvis, M. F; Berman, R. F Curr. Topics Med. Chem. 2005, 5, 43-58.

46. During, M. J.; Spencer, D. D. Ann. Neurol. 1992, 32, 618-624.

47. Boisson, D. Neuroscientist 2005, 11, 25-36.

48. Williams, M. In Handbook of Experimental Pharmacology-Purinergic and Pyrimidinergic Neurotransmission Vol. 151, Part 2; Abbracchio, M. P, Williams, M., Eds.; Springer-Verlag: Berlin, Germany, 2001, pp 407-434.

49. Huber, A.; Padrun, V; Deglon, N.; Aebischer, P.; Mohler, H.; Boison, D. Proc. Natl. Acad. Sci. USA 2001, 98, 7611-7616.

50. Guttinger, M.; Padrun, V; Pralong, W F; Boison, D. Exp. Neurol. 2005, 193, 53-65.

51. Schousboe, A.; Sarup, A.; Larsson, O. M.; White, H. S. Biochem. Pharmacol. 2004, 68, 1557-1563.

52. Andersen, K. E.; Braestrup, C.; Gr0nwald, F C.; J0rgensen, A. S.; Nielsen, E. B.; Sonnewald, U.; S0rensen, P. O.; Suzdak, P. D.; Knutsen, L. J. S. J. Med. Chem. 1993, 36, 1716-1725.

53. White, H. S.; Watson, W P.; Hansen, S. L.; Slough, S.; Perregaard, J.; Sarup, A.; Bolvig, T; Petersen, G.; Larsson, O. M.; Clausen, R. P et al. J. Pharmacol. Exp. Ther. 2005, 312, 866-874.

54. Richerson, G. B.; Wu, Y Adv. Exp. Med. Biol. 2004, 548, 76-91.

55. Yeun, A. W C.; Sander, J. W; Fluegel, D.; Patsalos, P N.; Bell, G. S.; Johnson, T; Koepp, M. J. Epilepsy Behav 2005, 7, 253-258.

Biographies

Lars J S Knutsen began his research career at Glaxo in Ware, Herts., UK having completed an MA in Chemistry at Christ Church, Oxford, in 1978. While at Glaxo he completed a PhD in Nucleoside Chemistry joining Novo Nordisk in Denmark in 1986. While there he led the project that identified tiagabine, a marketed anticonvulsant acting by blocking GABA uptake. In 1997, he joined Vernalis (Cerebrus) in the UK, initiating the adenosine A2A antagonist project that led to V2006, currently in clinical trials with Biogen-IDEC for Parkinson's disease. He joined Ionix Pharmaceuticals Ltd., in Cambridge, UK in 2002 as Director of Chemistry. Dr Knutsen joined the CNS Medicinal Chemistry group at Cephalon Inc. in 2006. He has over 35 peer-reviewed publications and 18 issued US patents.

Michael Williams received his PhD (1974) from the Institute of Psychiatry and his Doctor of Science degree in Pharmacology (1987) both from the University of London. Dr Williams has worked in the US-based pharmaceutical industry for 30 years at Merck, Sharp and Dohme Research Laboratories, Nova Pharmaceutical, CIBA-Geigy and Abbott Laboratories. He retired from the latter in 2000 and after serving as a consultant with various biotechnology/ pharmaceutical/venture capital companies in the US and Europe, joined Cephalon, Inc. in West Chester, in 2003 where he is vice president of Worldwide Discovery Research. He has published some 300 articles, book chapters and reviews and is an adjunct professor in the Department of Molecular Pharmacology and Biological Chemistry at the Feinberg School of Medicine, Northwestern University, Chicago, IL.

© 2007 Elsevier Ltd. All Rights Reserved Comprehensive Medicinal Chemistry II

No part of this publication may be reproduced, stored in any retrieval system or transmitted ISBN (set): 0-08-044513-6 in any form by any means electronic, electrostatic, magnetic tape, mechanical, photocopying, recording or otherwise, without permission in writing from the publishers ISBN (Volume 6) 0-08-044519-5; pp. 279-296

Blood Pressure Health

Blood Pressure Health

Your heart pumps blood throughout your body using a network of tubing called arteries and capillaries which return the blood back to your heart via your veins. Blood pressure is the force of the blood pushing against the walls of your arteries as your heart beats.Learn more...

Get My Free Ebook


Post a comment